Trevi Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Trevi Therapeutics, Inc. (TRVI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $14.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-17
- Trevi Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $14.00K.
- Trevi Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was -$15.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $14.00K 10-K · filed 2026-03-17 |
| 2024-12-31 | -$15.00K 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |